Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gen2 Isthmus-Dependent Atrial Flutter Ablation Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00606463
Recruitment Status : Terminated (Abbott funding allocated to a different project.)
First Posted : February 4, 2008
Last Update Posted : August 11, 2020
Sponsor:
Information provided by (Responsible Party):
Abbott Medical Devices

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Irrigated catheter for ablation of isthmus-dependent atrial flutter

Condition or disease Intervention/treatment Phase
Atrial Flutter Device: Cardiac Ablation (Gen2 Cardiac Ablation System) Not Applicable

Detailed Description:
This study intends to use an investigational irrigated catheter for ablation of isthmus-dependent atrial flutter
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Gen2 Cardiac Ablation System Isthmus-Dependent Atrial Flutter Study
Study Start Date : February 2008
Actual Primary Completion Date : August 2008
Actual Study Completion Date : January 2009
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: (Gen2 Cardiac Ablation System)
Ablation of isthmus-dependent atrial flutter
 Device: Cardiac Ablation (Gen2 Cardiac Ablation System)
Ablation of isthmus-dependent atrial flutter


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of intraprocedural, serious cardiac adverse event [ Time Frame: 7 days post-procedure ]
    Defined as the Incidence of intraprocedural, serious cardiac adverse event


Other Outcome Measures:
  1. Bi-direction block and non-inducibility of atrial flutter [ Time Frame: Procedural ]
    Acute Procedure success defined as bi-directional block and non-inducibility of atrial flutter


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Scheduled for ablation of isthmus-dependent atrial flutter

Exclusion Criteria:

  • Prior ablation of isthmus-dependent atrial flutter
  • Atypical or scar flutter
  • Significant heart disease
  • Intracardiac thrombus
  • Prior cardiac surgery (within 1 month)
  • Contraindication to heparin
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606463


Locations
Layout table for location information
United States, Alabama
University of Alabama Birmingham
Birmingham, Alabama, United States
United States, New Jersey
St. Barnabus Medical Center
West Orange, New Jersey, United States
United States, Pennsylvania
Doylestown Hospital
Doylestown, Pennsylvania, United States
Sponsors and Collaborators
Abbott Medical Devices
Investigators
Layout table for investigator information
Principal Investigator: Vance Plumb, MD University of Alabama at Birmingham
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Abbott Medical Devices
ClinicalTrials.gov Identifier: NCT00606463    
Other Study ID Numbers: 0611.1
First Posted: February 4, 2008    Key Record Dates
Last Update Posted: August 11, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Flutter
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes